Clinical Trial Update: Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients [Phase 4]

View source ↗

Summary

Phase 4 trial assessing bortezomib (Alvocade) in newly diagnosed multiple myeloma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Al-Rasheed University College | Conditions: Newly Diagnosed Multiple Myeloma | Phase 4 | Status: WITHDRAWN